Subtype
Ovarian Carcinoma
CI-CAN-00003517Explore in graph →
270 active trials2 approved drugs24 evidence items
- NCIt
- C4908
- DOID
- 2152
- DOID
- 4001
- MeSH
- D000077216
Loading cancer entity…
Subtype
CI-CAN-00003517Explore in graph →
Clinical trials
895 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 |
| clinicaltrials |
Data updated 22 days agoSource updated Apr 15, 2022source: clinicaltrials